Century Therapeutics Q2 2024 GAAP EPS $(0.38) Beats $(0.47) Estimate, Sales $771.000K Miss $1.931M Estimate
Portfolio Pulse from Benzinga Newsdesk
Century Therapeutics (NASDAQ:IPSC) reported Q2 2024 GAAP EPS of $(0.38), beating the $(0.47) estimate, but missed sales estimates with $771K against $1.931M. EPS improved by 32.14% YoY, while sales increased by 678.79% YoY.
August 08, 2024 | 11:52 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Century Therapeutics reported better-than-expected EPS for Q2 2024, but missed sales estimates significantly. EPS improved by 32.14% YoY, while sales saw a substantial increase of 678.79% YoY.
The better-than-expected EPS is a positive sign, but the significant miss on sales estimates could offset this. The YoY improvements in both EPS and sales are notable, but the mixed results may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100